Pricing Log in Create free account
Monday 9 November 2026 Export AYTU’s income statement to Excel — free account

Aytu BioPharma, Inc.

AYTU

Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.

Revenue
+6.42%
EPS
+100.0%
Free cash flow
+57.7%
Total debt
−21.9%

Quarter to June 2026, against a year earlier

1.83 0.02 +1.10%
Market cap
$19.9M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
3/9
ROIC
−20.0%
Net debt / EBITDA
2.2×
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Net bought
—
Trades
0 sells · 0 buys
Ownership
19.1%

Capital & Financial Ratios $m

Size
Market Cap 20
Revenue ttm 58
Net income ttm (14)
Free cash flow ttm 3
Net debt Q (9)
Valuation
P/E n/m
Forward P/E n/m
Price / sales 0.4
Forward P/S Powerpack
Price / FCF 7.0
Price / book 0.6
Financial health
Current ratio Q 1.1
Debt / equity Q 0.5 (at or below 0.5: strong)
Interest coverage Q (2.0)
Growth
Revenue growth Q +6.4% (above 0%: growing)
Operating income growth Q +89.8% (above 0%: growing)
EPS, this year +46.3% (at or above 15%: strong)
EPS, next year A +143.3% (at or above 15%: strong)
Revenue, next year A +18.0% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 0.2×; over the ten years it ranged from −5.2× in 2016 to 33.4× in 2017.
P/S against its own 10 years 39.53%
10-year low 10-year high
P/B against its own 10 years 55.28%
10-year low 10-year high
EV/Sales against its own 10 years 36.33%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 23 20 31 26
Receivables 29 24 31 23
Inventory 12 12 11 7
Other — — — —
71 62 79 62
2023 2024 2025 2026
Payables 13 10 11 11
ST’ Debt 2 4 11 8
Other 7 9 3 0
69 62 63 55

Compound Annual Growth %

10y 5y 3y
Sales 36.51% (2.59%) (18.77%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 13.34% (23.83%) (3.59%)

Earnings Trends EPS, adjusted, against the consensus

Q4 FY26 Estimate −0.22 Actual −0.05

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY26 −0.06 −0.08 Miss by 0.02
Q2 FY26 −0.26 −1.05 Miss by 0.79
Q3 FY26 −0.31 −0.53 Miss by 0.22
Q4 FY26 −0.22 −0.05 Beat by 0.17
Q1 FY27 −0.10 — Reports 12 November 2026

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 (0.08) (1.05) (0.53) 0.00 (1.16)
’25 0.15 (0.26) 0.21 (2.92) (2.16)
’24 (1.48) (0.04) (0.52) (0.82) (2.86)
’23 (0.28) (2.15) (1.93) (0.59) (5.11)
’22 (21.80) (8.80) (35.80) (9.80) (75.00)
’21 (8.00) (14.40) (28.20) (20.04) (69.60)
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 14 15 12 16 58
’25 17 16 18 15 66
’24 18 19 14 15 65
’23 28 26 23 31 107
’22 22 23 24 27 97
’21 14 15 13 23 66
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (1) 4 (4) 4 3
’25 (1) 3 (6) 3 (2)
’24 0 0 0 (1) (1)
’23 (9) (2) (3) 9 (5)
’22 (4) (9) (9) (7) (29)
’21 (8) (3) (9) (6) (26)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (1) 4 (4) 4 3
’25 (1) 3 (7) 3 (1)
’24 0 0 0 (1) (2)
’23 (9) (2) (3) 9 (5)
’22 (4) (9) (9) (7) (29)
’21 (8) (3) (9) (9) (28)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 3 4 7 28 66 97 107 65 66 58 +37.8% 68 87 116 +26.4%
Gross margin, % 56.00 43.98 69.92 70.03 44.49 54.08 62.04 75.26 69.04 63.95 +7.9 pt
EBT (23) (10) (27) (14) (58) (109) (17) (10) (14) (14) (5.0%)
EBT margin, % (698.67) (278.35) (370.63) (49.29) (88.42) (112.64) (15.88) (15.92) (20.71) (24.72) +673.9 pt
Net income (23) (10) (27) (14) (58) (109) (17) (16) (14) (14) (5.0%)
Per share, $
Per share, $ Revenue 1,400.70 1,109.12 187.70 122.27 78.38 65.76 32.16 11.77 10.57 4.67 (46.9%)
Earnings (9,659.72) (3,062.00) (696.00) (60.28) (69.60) (75.00) (5.11) (2.86) (2.16) (1.16) (63.3%)
Cash flow (6,012.91) (4,830.39) (354.65) (125.55) (31.01) (19.61) (1.54) (0.25) (0.31) 0.27 n/m
Capex (48.52) (143.85) (14.35) (25.88) (2.80) 0.00 0.00 (0.06) 0.07 0.00 (66.8%)
Free cash flow (6,061.43) (4,974.24) (369.01) (151.43) (33.80) (19.61) (1.54) (0.31) (0.24) 0.26 n/m
Book value 1,739.04 4,068.03 181.74 420.42 164.28 30.14 11.78 5.00 3.02 2.86 (50.9%)
Shares, m 0 0 0 0 1 1 3 6 6 12 +159.6%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 33.70 0.96 2.05 2.32 1.28 0.21 0.05 0.24 0.21 0.46 4.1
P/B 27.14 0.26 2.11 0.68 0.61 0.46 0.14 0.57 0.72 0.75 3.3
EV/Sales 33.43 (0.99) 1.20 1.10 0.90 0.20 (0.01) 0.17 0.07 0.30 3.6
EV/FCF (7.72) 0.22 (0.61) (0.76) (1.47) (0.45) 0.07 (0.97) (3.04) 5.32 (0.9)
Cash, $m
Cash, $m Operating cash flow (14) (16) (14) (28) (26) (29) (5) (1) (2) 3 n/m
Capex 0 0 (1) (6) (2) — — 0 0 0 (13.9%)
Free cash flow (14) (16) (14) (34) (28) (29) (5) (2) (1) 3 n/m
Balance, $m
Balance, $m Working capital (1) 6 10 47 (4) (5) 2 0 16 7 n/m
Net debt (1) (7) (11) (34) (25) (1) (7) (5) (9) (9) +30.0%
Shareholders’ equity 4 13 7 95 138 44 39 28 19 35 +27.4%
Returns, %
Returns, % ROA (114.43) (56.51) (97.28) (14.49) (27.83) (53.95) (12.44) (12.45) (11.20) (12.44) +102.0 pt
ROIC (402.85) (195.07) 0.00 (21.59) (32.72) (159.24) (32.58) (4.35) (49.77) (19.99) +382.9 pt
ROE (319.60) (116.94) (264.55) (26.68) (50.12) (119.62) (40.76) (47.24) (58.10) (52.55) +267.1 pt
People
People Employees 63 57 53 75 175 164 150 102 83 76 +2.1%
Revenue/emp, $m 0.05 0.06 0.14 0.37 0.38 0.59 0.72 0.64 0.80 0.76 +34.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Aytu BioPharma, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SCYX SCYNEXIS, Inc. $34.8M — (loss-making) — (loss-making) −8.56% (below 0%: shrinking) n/m −98.60% (below 0%: shrinking) 100.00% (3,308.51%) Compare
RMTI Rockwell Medical, Inc. $31.2M — (loss-making) — (loss-making) +10.63% (above 0%: growing) n/m −12.92% (below 0%: shrinking) 18.24% (5.97%) Compare
IXHL Incannex Healthcare Inc. $28.1M — (loss-making) — (loss-making) −92.31% (below 0%: shrinking) n/m +327.73% (above 0%: growing) 100.00% 0.00% Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc. $26.6M — (loss-making) — — n/m +82.01% (above 0%: growing) 0.00% 0.00% Compare
CPHI China Pharma Holdings, Inc. $24.5M — (loss-making) — (loss-making) −7.56% (below 0%: shrinking) n/m −113.57% (below 0%: shrinking) 8.82% (150.99%) Compare
TXMD TherapeuticsMD, Inc. $20.1M — (loss-making) 18.9× −8.72% (below 0%: shrinking) −80.00% (below 0%: shrinking) +104.46% (above 0%: growing) 100.00% (93.90%) Compare
AYTU Aytu BioPharma, Inc. $19.9M — (loss-making) — (loss-making) +6.42% (above 0%: growing) n/m +57.72% (above 0%: growing) 64.63% (4.82%)
OPTH Optimi Health Corp. $13.4M — — — n/m — 89.93% (1,364.28%) Compare
BFRI Biofrontera Inc. $12.3M — (loss-making) — (loss-making) +32.92% (above 0%: growing) n/m +45.57% (above 0%: growing) 79.92% (4.37%) Compare
Median of peers $25.6M — — −8.06% — +45.57% 84.93% (49.93%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 22 October 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 844.85k 854.77k 134.38
2025 883.93k 867.09k 136.25
2024 928.22k 919.18k 182.50

Ownership

Directors and executive officers, together 6.14%
Nantahala Capital Management, LLC 10.00%
Stonepine Capital Management, LLC 9.99%
AWM Investment Company, Inc. 5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Aytu BioPharma, Inc. (AYTU) Latest News

23 Sep

Impact 4 · · Moby transcript
Impact 4 ·
Impact 4 · · ACCESS Newswire

22 Sep

Impact 4 ·
Impact 3 · · Zacks

14 May

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

13 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · Benzinga transcript
Impact 3 · · Zacks
Impact 3 · · ACCESS Newswire

30 Apr

Impact 3 ·

5 Feb

Impact 4 · · Simply Wall St.

4 Feb

Impact 3 · · GuruFocus.com transcript

3 Feb

Impact 4 · · Moby
Impact 3 · · Zacks
Impact 3 · · ACCESS Newswire

2 Feb

Impact 4 · · Zacks

20 Jan

Impact 4 · · ACCESS Newswire
Impact 3 · · ACCESS Newswire

12 Jan

Impact 3 · · ACCESS Newswire

18 Dec

Impact 3 · · ACCESS NewswireMT NewswiresMT NewswiresInvesting.comMotley FoolMT NewswiresMT NewswiresMT Newswires

15 Dec

Impact 4 ·

21 Nov

Impact 3 · · Simply Wall St.

14 Nov

Impact 4 · · GuruFocus.comGuruFocus.com transcript

13 Nov

Impact 3 · · ZacksGuruFocus.comZacksZacksZacksZacksBarchartZacks
Impact 3 · · ACCESS Newswire

28 Oct

Impact 4 · · ACCESS Newswire

24 Sep

Impact 4 · · GuruFocus.com transcript
Impact 3 · · ACCESS NewswireGuruFocus.comMT NewswiresSimply Wall St.TipRanks
stockrow.com/AYTU · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com